Search

Your search keyword '"SORIANO, Alessandra"' showing total 162 results
Start Over Author "SORIANO, Alessandra" Search Limiters Available in Library Collection
162 results on '"SORIANO, Alessandra"'

2. Proof-of-Concept Human Organ-on-Chip Study: First Step of Platform to Assess Neuro-Immunological Communication Involved in Inflammatory Bowel Diseases

Author

Gabriel-Segard, Tristan, primary, Rontard, Jessica, additional, Miny, Louise, additional, Dubuisson, Louise, additional, Batut, Aurélie, additional, Debis, Delphine, additional, Gleyzes, Mélanie, additional, François, Fabien, additional, Larramendy, Florian, additional, Soriano, Alessandra, additional, Honegger, Thibault, additional, and Paul, Stéphane, additional

Published
2023
Full Text
View/download PDF

4. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves

Author

Bezzio, Cristina, Vernero, Marta, Costa, Stefania, Armuzzi, Alessandro, Fiorino, Gionata, Ardizzone, Sandro, Roselli, Jenny, Carparelli, Sonia, Orlando, Ambrogio, Caprioli, Flavio Andrea, Castiglione, Fabiana, Viganò, Chiara, Ribaldone, Davide G., Zingone, Fabiana, Monterubbianesi, Rita, Imperatore, Nicola, Festa, Stefano, Daperno, Marco, Scucchi, Ludovica, Ferronato, Antonio, Pastorelli, Luca, Alimenti, Eleonora, Balestrieri, Paola, Ricci, Chiara, Cappello, Maria, Felice, Carla, Coppini, Francesca, Alvisi, Patrizia, Di Luna, Imma, Gerardi, Viviana, Variola, Angela, Mazzuoli, Silvia, Lenti, Marco Vincenzo, Saibeni, Simone, Pugliese, Daniela, Furfaro, Federica, Maconi, Giovanni, Milla, Monica, Bossa, Fabrizio, Giuliano, Alessandra, Piazza, Nicole, Manes, Gianpiero, Sartini, Alessandro, Buda, Andrea, Micheli, Federica, Ciardo, Valeria, Casella, Giovanni, Viscido, Angelo, Bodini, Giorgia, Casini, Valentina, Soriano, Alessandra, Amato, Arnaldo, Grossi, Laurino, Onali, Sara, Rottoli, Matteo, Spagnuolo, Rocco, Baroni, Stefania, Cortelezzi, Claudio, Baldoni, Monia, Scaldaferri, Franco, Guarino, Alessia, Palermo, Andrea, D’Incà, Renata, Scribano, Maria Lia, Biancone, Livia, Carrozza, Lucio, Ascolani, Marta, Costa, Francesco, Di Sabatino, Antonio, Zammarchi, Irene, Gottin, Matteo, Conforti, Francesco Simone, Null, Null, Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), Scaldaferri, Franco (ORCID:0000-0001-8334-7541), Bezzio, Cristina, Vernero, Marta, Costa, Stefania, Armuzzi, Alessandro, Fiorino, Gionata, Ardizzone, Sandro, Roselli, Jenny, Carparelli, Sonia, Orlando, Ambrogio, Caprioli, Flavio Andrea, Castiglione, Fabiana, Viganò, Chiara, Ribaldone, Davide G., Zingone, Fabiana, Monterubbianesi, Rita, Imperatore, Nicola, Festa, Stefano, Daperno, Marco, Scucchi, Ludovica, Ferronato, Antonio, Pastorelli, Luca, Alimenti, Eleonora, Balestrieri, Paola, Ricci, Chiara, Cappello, Maria, Felice, Carla, Coppini, Francesca, Alvisi, Patrizia, Di Luna, Imma, Gerardi, Viviana, Variola, Angela, Mazzuoli, Silvia, Lenti, Marco Vincenzo, Saibeni, Simone, Pugliese, Daniela, Furfaro, Federica, Maconi, Giovanni, Milla, Monica, Bossa, Fabrizio, Giuliano, Alessandra, Piazza, Nicole, Manes, Gianpiero, Sartini, Alessandro, Buda, Andrea, Micheli, Federica, Ciardo, Valeria, Casella, Giovanni, Viscido, Angelo, Bodini, Giorgia, Casini, Valentina, Soriano, Alessandra, Amato, Arnaldo, Grossi, Laurino, Onali, Sara, Rottoli, Matteo, Spagnuolo, Rocco, Baroni, Stefania, Cortelezzi, Claudio, Baldoni, Monia, Scaldaferri, Franco, Guarino, Alessia, Palermo, Andrea, D’Incà, Renata, Scribano, Maria Lia, Biancone, Livia, Carrozza, Lucio, Ascolani, Marta, Costa, Francesco, Di Sabatino, Antonio, Zammarchi, Irene, Gottin, Matteo, Conforti, Francesco Simone, Null, Null, Armuzzi, Alessandro (ORCID:0000-0003-1572-0118), and Scaldaferri, Franco (ORCID:0000-0001-8334-7541)

Abstract

BackgroundIn Italy, the incidence of SARS-CoV-2 infection peaked in April and November 2020, defining two pandemic waves of coronavirus disease 2019 (COVID-19). This study compared the characteristics and outcomes of patients with inflammatory bowel disease (IBD) and SARS-CoV-2 infections between pandemic waves.MethodsObservational longitudinal study of IBD patients with SARS-CoV-2 infection. Patients with established diagnoses of IBD and of SARS-CoV-2 infection were consecutively enrolled in two periods: (i) first wave, from 1 March 2020 to 31 May 2020; and (ii) second wave, from 15 September to 15 December 2020.ResultsWe enrolled 937 IBD patients (219 in the first wave, 718 in the second wave). Patients of the first wave were older (mean & PLUSMN; SD: 46.3 & PLUSMN; 16.2 vs. 44.1 & PLUSMN; 15.4 years, p = 0.06), more likely to have ulcerative colitis (58.0% vs. 44.4%, p < 0.001) and comorbidities (48.9% vs. 38.9%; p < 0.01), and more frequently residing in Northern Italy (73.1% vs. 46.0%, p < 0.001) than patients of the second wave. There were no significant differences between pandemic waves in sex (male: 54.3% vs. 53.3%, p = 0.82) or frequency of active IBD (44.3% vs. 39.0%, p = 0.18). The rates of negative outcomes were significantly higher in the first than second wave: pneumonia (27.8% vs. 11.7%, p < 0.001), hospital admission (27.4% vs. 9.7%, p < 0.001), ventilatory support (11.9% vs. 5.4%, p < 0.003) and death (5.5% vs. 1.8%, p < 0.007).ConclusionBetween the first and second SARS-CoV-2 pandemic waves, demographic, clinical and geographical features of IBD patients were different as were the symptoms and outcomes of infection. These differences are likely due to the different epidemiological situations and diagnostic possibilities between the two waves.

Published
2023

7. Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach

Author

Zanelli, Magda, primary, Palicelli, Andrea, additional, Sanguedolce, Francesca, additional, Zizzo, Maurizio, additional, Filosa, Alessandra, additional, Ricci, Linda, additional, Cresta, Camilla, additional, Martino, Giovanni, additional, Bisagni, Alessandra, additional, Zanetti, Eleonora, additional, di Donato, Francesco, additional, Melli, Beatrice, additional, Soriano, Alessandra, additional, Cimino, Luca, additional, Cavazza, Alberto, additional, Vivian, Lisa Francesca, additional, and Ascani, Stefano, additional

Published
2022
Full Text
View/download PDF

8. Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls

Author

Zanelli, Magda, primary, Sanguedolce, Francesca, additional, Zizzo, Maurizio, additional, Palicelli, Andrea, additional, Pellegrini, David, additional, Farinacci, Sabrina, additional, Soriano, Alessandra, additional, Froio, Elisabetta, additional, Cormio, Luigi, additional, Carrieri, Giuseppe, additional, Cavazza, Alberto, additional, Merli, Francesco, additional, Pileri, Stefano A., additional, and Ascani, Stefano, additional

Published
2022
Full Text
View/download PDF

10. EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3)

Author

Zanelli, Magda, primary, Sanguedolce, Francesca, additional, Palicelli, Andrea, additional, Zizzo, Maurizio, additional, Martino, Giovanni, additional, Caprera, Cecilia, additional, Fragliasso, Valentina, additional, Soriano, Alessandra, additional, Gozzi, Fabrizio, additional, Cimino, Luca, additional, Masia, Francesco, additional, Moretti, Marina, additional, Foroni, Moira, additional, De Marco, Loredana, additional, Pellegrini, David, additional, De Raeve, Hendrik, additional, Ricci, Stefano, additional, Tamagnini, Ione, additional, Tafuni, Alessandro, additional, Cavazza, Alberto, additional, Merli, Francesco, additional, Pileri, Stefano A., additional, and Ascani, Stefano, additional

Published
2021
Full Text
View/download PDF

11. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment

Author

Palicelli, Andrea, primary, Croci, Stefania, additional, Bisagni, Alessandra, additional, Zanetti, Eleonora, additional, De Biase, Dario, additional, Melli, Beatrice, additional, Sanguedolce, Francesca, additional, Ragazzi, Moira, additional, Zanelli, Magda, additional, Chaux, Alcides, additional, Cañete-Portillo, Sofia, additional, Bonasoni, Maria Paola, additional, Soriano, Alessandra, additional, Ascani, Stefano, additional, Zizzo, Maurizio, additional, Castro Ruiz, Carolina, additional, De Leo, Antonio, additional, Giordano, Guido, additional, Landriscina, Matteo, additional, Carrieri, Giuseppe, additional, Cormio, Luigi, additional, Berney, Daniel M., additional, Gandhi, Jatin, additional, Copelli, Valerio, additional, Bernardelli, Giuditta, additional, Santandrea, Giacomo, additional, and Bonacini, Martina, additional

Published
2021
Full Text
View/download PDF

12. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1

Author

Palicelli, Andrea, primary, Croci, Stefania, additional, Bisagni, Alessandra, additional, Zanetti, Eleonora, additional, De Biase, Dario, additional, Melli, Beatrice, additional, Sanguedolce, Francesca, additional, Ragazzi, Moira, additional, Zanelli, Magda, additional, Chaux, Alcides, additional, Cañete-Portillo, Sofia, additional, Bonasoni, Maria Paola, additional, Soriano, Alessandra, additional, Ascani, Stefano, additional, Zizzo, Maurizio, additional, Castro Ruiz, Carolina, additional, De Leo, Antonio, additional, Giordano, Guido, additional, Landriscina, Matteo, additional, Carrieri, Giuseppe, additional, Cormio, Luigi, additional, Berney, Daniel M., additional, Gandhi, Jatin, additional, Nicoli, Davide, additional, Farnetti, Enrico, additional, Santandrea, Giacomo, additional, and Bonacini, Martina, additional

Published
2021
Full Text
View/download PDF

13. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models)

Author

Palicelli, Andrea, primary, Croci, Stefania, additional, Bisagni, Alessandra, additional, Zanetti, Eleonora, additional, De Biase, Dario, additional, Melli, Beatrice, additional, Sanguedolce, Francesca, additional, Ragazzi, Moira, additional, Zanelli, Magda, additional, Chaux, Alcides, additional, Cañete-Portillo, Sofia, additional, Bonasoni, Maria Paola, additional, Soriano, Alessandra, additional, Ascani, Stefano, additional, Zizzo, Maurizio, additional, Castro Ruiz, Carolina, additional, De Leo, Antonio, additional, Giordano, Guido, additional, Landriscina, Matteo, additional, Carrieri, Giuseppe, additional, Cormio, Luigi, additional, Berney, Daniel M., additional, Gandhi, Jatin, additional, Santandrea, Giacomo, additional, and Bonacini, Martina, additional

Published
2021
Full Text
View/download PDF

14. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Author

Palicelli, Andrea, primary, Bonacini, Martina, additional, Croci, Stefania, additional, Magi-Galluzzi, Cristina, additional, Cañete-Portillo, Sofia, additional, Chaux, Alcides, additional, Bisagni, Alessandra, additional, Zanetti, Eleonora, additional, De Biase, Dario, additional, Melli, Beatrice, additional, Sanguedolce, Francesca, additional, Zanelli, Magda, additional, Bonasoni, Maria Paola, additional, De Marco, Loredana, additional, Soriano, Alessandra, additional, Ascani, Stefano, additional, Zizzo, Maurizio, additional, Castro Ruiz, Carolina, additional, De Leo, Antonio, additional, Giordano, Guido, additional, Landriscina, Matteo, additional, Carrieri, Giuseppe, additional, Cormio, Luigi, additional, Berney, Daniel M., additional, Gandhi, Jatin, additional, Santandrea, Giacomo, additional, Gelli, Maria Carolina, additional, Tafuni, Alessandro, additional, and Ragazzi, Moira, additional

Published
2021
Full Text
View/download PDF

15. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Author

Palicelli, Andrea, primary, Bonacini, Martina, additional, Croci, Stefania, additional, Magi-Galluzzi, Cristina, additional, Cañete-Portillo, Sofia, additional, Chaux, Alcides, additional, Bisagni, Alessandra, additional, Zanetti, Eleonora, additional, De Biase, Dario, additional, Melli, Beatrice, additional, Sanguedolce, Francesca, additional, Ragazzi, Moira, additional, Bonasoni, Maria Paola, additional, Soriano, Alessandra, additional, Ascani, Stefano, additional, Zizzo, Maurizio, additional, Castro Ruiz, Carolina, additional, De Leo, Antonio, additional, Giordano, Guido, additional, Landriscina, Matteo, additional, Carrieri, Giuseppe, additional, Cormio, Luigi, additional, Berney, Daniel M., additional, Athanazio, Daniel, additional, Gandhi, Jatin, additional, Cavazza, Alberto, additional, Santandrea, Giacomo, additional, Tafuni, Alessandro, additional, and Zanelli, Magda, additional

Published
2021
Full Text
View/download PDF

16. EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)

Author

Zanelli, Magda, primary, Sanguedolce, Francesca, additional, Palicelli, Andrea, additional, Zizzo, Maurizio, additional, Martino, Giovanni, additional, Caprera, Cecilia, additional, Fragliasso, Valentina, additional, Soriano, Alessandra, additional, Valle, Luca, additional, Ricci, Stefano, additional, Cavazza, Alberto, additional, Merli, Francesco, additional, Pileri, Stefano A., additional, and Ascani, Stefano, additional

Published
2021
Full Text
View/download PDF

17. EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2)

Author

Zanelli, Magda, primary, Sanguedolce, Francesca, additional, Palicelli, Andrea, additional, Zizzo, Maurizio, additional, Martino, Giovanni, additional, Caprera, Cecilia, additional, Fragliasso, Valentina, additional, Soriano, Alessandra, additional, Valle, Luca, additional, Ricci, Stefano, additional, Gozzi, Fabrizio, additional, Cimino, Luca, additional, Cavazza, Alberto, additional, Merli, Francesco, additional, Pileri, Stefano A., additional, and Ascani, Stefano, additional

Published
2021
Full Text
View/download PDF

18. Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10 ® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies.

Author

Berger, Anne Emmanuelle, Gleizes, Aude, Waeckel, Louis, Roblin, Xavier, Krzysiek, Roman, Hacein-Bey-Abina, Salima, Soriano, Alessandra, and Paul, Stephane

Subjects
ADALIMUMAB, CHEMILUMINESCENCE immunoassay, IMMUNOGLOBULINS, INFLIXIMAB, BIOLOGICAL monitoring, DRUG dosage
Abstract

Background. Monitoring of biological TNF inhibitors is a very important tool to guide clinical decisions using specialized algorithms, especially in gastroenterology. A new chemiluminescent instrument (i-TRACK10® from Theradiag) could replace ELISA techniques to calculate the dosage of drugs and anti-drug antibodies. In this bi-centric study, we explored the analytical performances of i-TRACK10® using manual or automated (DS2®) ELISA Lisa-Tracker® assays, and compared the results. Patients and methods. Intra- and inter-run performances were evaluated with i-TRACK10® in two different laboratories and for two different ranges of values for infliximab, adalimumab, and their respective antibodies. Patients' samples were used in the labs to compare the results obtained between the new instrument and either the manual Lisa-Tracker® or the automated DS2. Results. Intra- and inter-run performances were satisfactory, with values between 1.8% and 16.1% (for inter-run imprecision at low/medium values of infliximab). Results were generally comparable between assays. with the lowest value of correlation at 0.59 (anti-adalimumab dosage between i-TRACK10® and manual ELISA). Most often, values of drugs and anti-drug antibodies were higher with i-TRACK10® than with manual ELISA assay, and correlation values were better with automated ELISA. Agreements were globally acceptable, and the lowest coefficients of 0.7 was obtained for adalimumab values between i-TRACK10® and the two ELISA methods, and for anti-adalimumab values between i-TRACK10® and manual ELISA. The type of assay can potentially induce a change in the class of patients and lead to divergent therapeutic decisions. Conclusions. The new random-access instrument i-TRACK10® presents many advantages in a routine laboratory: rapidity, the possibility of standardization, usability, and expansion of the measurement range. Despite the relatively good agreement of results, it is preferable to use the same assay in longitudinal follow-up of a patient, because quantitative results were not completely equivalent especially for anti-drug antibodies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

19. Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome—Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network

Author

Vitale, Antonio, primary, Obici, Laura, additional, Cattalini, Marco, additional, Lopalco, Giuseppe, additional, Merlini, Giampaolo, additional, Ricco, Nicola, additional, Soriano, Alessandra, additional, La Torre, Francesco, additional, Verrecchia, Elena, additional, Insalaco, Antonella, additional, Dagna, Lorenzo, additional, Jaber, Masen Abdel, additional, Montin, Davide, additional, Emmi, Giacomo, additional, Ciarcia, Luisa, additional, Barneschi, Sara, additional, Parronchi, Paola, additional, Ruscitti, Piero, additional, Maggio, Maria Cristina, additional, Viapiana, Ombretta, additional, Sota, Jurgen, additional, Gaggiano, Carla, additional, Giacomelli, Roberto, additional, Sicignano, Ludovico Luca, additional, Manna, Raffaele, additional, Renieri, Alessandra, additional, Lo Rizzo, Caterina, additional, Frediani, Bruno, additional, Rigante, Donato, additional, and Cantarini, Luca, additional

Published
2021
Full Text
View/download PDF

20. Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach

Author

Zanelli, Magda, primary, Pizzi, Marco, additional, Sanguedolce, Francesca, additional, Zizzo, Maurizio, additional, Palicelli, Andrea, additional, Soriano, Alessandra, additional, Bisagni, Alessandra, additional, Martino, Giovanni, additional, Caprera, Cecilia, additional, Moretti, Marina, additional, Masia, Francesco, additional, De Marco, Loredana, additional, Froio, Elisabetta, additional, Foroni, Moira, additional, Bernardelli, Giuditta, additional, Alvarez de Celis, Maria Isabel, additional, Giunta, Alessandro, additional, Merli, Francesco, additional, and Ascani, Stefano, additional

Published
2021
Full Text
View/download PDF

21. T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker

Author

Zanelli, Magda, primary, Loscocco, Giuseppe G., additional, Sabattini, Elena, additional, Zizzo, Maurizio, additional, Sanguedolce, Francesca, additional, Panico, Luigi, additional, Fanni, Daniela, additional, Santi, Raffaella, additional, Caprera, Cecilia, additional, Rossi, Cristiana, additional, Soriano, Alessandra, additional, Cavazza, Alberto, additional, Giunta, Alessandro, additional, Mecucci, Cristina, additional, Vannucchi, Alessandro M., additional, Pileri, Stefano A., additional, and Ascani, Stefano, additional

Published
2021
Full Text
View/download PDF

23. sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care

Author

Saibeni, Simone, Scucchi, Ludovica, Dragoni, Gabriele, Bezzio, Cristina, Miranda, Agnese, Ribaldone, Davide Giuseppe, Bertani, Angela, Bossa, Fabrizio, Allocca, Mariangela, Buda, Andrea, Mocci, Gianmarco, Soriano, Alessandra, Mazzuoli, Silvia, Bertani, Lorenzo, Baccini, Flavia, Loddo, Erika, Privitera, Antonino Carlo, Sartini, Alessandro, Viscido, Angelo, Grossi, Laurino, Casini, Valentina, Gerardi, Viviana, Ascolani, Marta, Ruscio, Mirko Di, Casella, Giovanni, Savarino, Edoardo, Stradella, Davide, Pumpo, Rossella, Cortelezzi, Claudio Camillo, Daperno, Marco, Ciardo, Valeria, Nardone, Olga Maria, Caprioli, Flavio, Vitale, Giovanna, Cappello, Maria, Comberlato, Michele, Alvisi, Patrizia, Festa, Stefano, Campigotto, Michele, Bodini, Giorgia, Balestrieri, Paola, Viola, Anna, Pugliese, Daniela, Armuzzi, Alessandro, Fantini, Massimo C, and Fiorino, Gionata

Subjects
FOS: Clinical medicine, FOS: Biological sciences, 111199 Nutrition and Dietetics not elsewhere classified, FOS: Health sciences, 110308 Geriatrics and Gerontology, 69999 Biological Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620964132 for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care by Simone Saibeni, Ludovica Scucchi, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Gianmarco Mocci, Alessandra Soriano, Silvia Mazzuoli, Lorenzo Bertani, Flavia Baccini, Erika Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Stradella, Rossella Pumpo, Claudio Camillo Cortelezzi, Marco Daperno, Valeria Ciardo, Olga Maria Nardone, Flavio Caprioli, Giovanna Vitale, Maria Cappello, Michele Comberlato, Patrizia Alvisi, Stefano Festa, Michele Campigotto, Giorgia Bodini, Paola Balestrieri, Anna Viola, Daniela Pugliese, Alessandro Armuzzi, Massimo C Fantini, Gionata Fiorino and on behalf of IG-IBD (Italian Group for the study of Inflammatory Bowel Disease) in United European Gastroenterology Journal

Published
2020
Full Text
View/download PDF

24. Primary Pulmonary B-Cell Lymphoma: A Review and Update

Author

Sanguedolce, Francesca, primary, Zanelli, Magda, additional, Zizzo, Maurizio, additional, Bisagni, Alessandra, additional, Soriano, Alessandra, additional, Cocco, Giorgia, additional, Palicelli, Andrea, additional, Santandrea, Giacomo, additional, Caprera, Cecilia, additional, Corsi, Matteo, additional, Cerrone, Giulia, additional, Sciaccotta, Raffaele, additional, Martino, Giovanni, additional, Ricci, Linda, additional, Sollitto, Francesco, additional, Loizzi, Domenico, additional, and Ascani, Stefano, additional

Published
2021
Full Text
View/download PDF

25. Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network

Author

Gaggiano, Carla, primary, Rigante, Donato, additional, Hernández-Rodríguez, José, additional, Vitale, Antonio, additional, Tarsia, Maria, additional, Soriano, Alessandra, additional, Lopalco, Giuseppe, additional, Iannone, Florenzo, additional, Abdel Jaber, Masen, additional, Giacomelli, Roberto, additional, Wiȩsik-Szewczyk, Ewa, additional, Cattalini, Marco, additional, Frassi, Micol, additional, Piga, Matteo, additional, Ragab, Gaafar, additional, Sota, Jurgen, additional, Zunica, Fiammetta, additional, Floris, Alberto, additional, Sabato, Vito, additional, Hegazy, Mohamed Tharwat, additional, Araújo, Olga, additional, Pelegrín, Laura, additional, Fabbiani, Alessandra, additional, Renieri, Alessandra, additional, Grosso, Salvatore, additional, Fabiani, Claudia, additional, Frediani, Bruno, additional, and Cantarini, Luca, additional

Published
2021
Full Text
View/download PDF

26. Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network

Author

Gaggiano, Carla, primary, Vitale, Antonio, additional, Obici, Laura, additional, Merlini, Giampaolo, additional, Soriano, Alessandra, additional, Viapiana, Ombretta, additional, Cattalini, Marco, additional, Maggio, Maria Cristina, additional, Lopalco, Giuseppe, additional, Montin, Davide, additional, Jaber, Masen Abdel, additional, Dagna, Lorenzo, additional, Manna, Raffaele, additional, Insalaco, Antonella, additional, Piga, Matteo, additional, La Torre, Francesco, additional, Berlengiero, Virginia, additional, Gelardi, Viviana, additional, Ciarcia, Luisa, additional, Emmi, Giacomo, additional, Ruscitti, Piero, additional, Caso, Francesco, additional, Cimaz, Rolando, additional, Hernández-Rodríguez, José, additional, Parronchi, Paola, additional, Sicignano, Ludovico Luca, additional, Verrecchia, Elena, additional, Iannone, Florenzo, additional, Sota, Jurgen, additional, Grosso, Salvatore, additional, Salvarani, Carlo, additional, Frediani, Bruno, additional, Giacomelli, Roberto, additional, Mencarelli, Maria Antonietta, additional, Renieri, Alessandra, additional, Rigante, Donato, additional, and Cantarini, Luca, additional

Published
2020
Full Text
View/download PDF

29. Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

Author

Vitale, Antonio, primary, Sota, Jurgen, additional, Obici, Laura, additional, Ricco, Nicola, additional, Maggio, Maria Cristina, additional, Cattalini, Marco, additional, Ruscitti, Piero, additional, Caso, Francesco, additional, Manna, Raffaele, additional, Viapiana, Ombretta, additional, Caggiano, Valeria, additional, Emmi, Giacomo, additional, Insalaco, Antonella, additional, Montin, Davide, additional, Licciardi, Francesco, additional, Soriano, Alessandra, additional, Dagna, Lorenzo, additional, Salvarani, Carlo, additional, Lamacchia, Vittoria, additional, Hernández-Rodríguez, José, additional, Giacomelli, Roberto, additional, Frediani, Bruno, additional, Renieri, Alessandra, additional, and Cantarini, Luca, additional

Published
2020
Full Text
View/download PDF

30. Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases

Author

Bonacini, Martina, primary, Soriano, Alessandra, additional, Cimino, Luca, additional, De Simone, Luca, additional, Bolletta, Elena, additional, Gozzi, Fabrizio, additional, Muratore, Francesco, additional, Nicastro, Maria, additional, Belloni, Lucia, additional, Zerbini, Alessandro, additional, Fontana, Luigi, additional, Salvarani, Carlo, additional, and Croci, Stefania, additional

Published
2020
Full Text
View/download PDF

32. Correction: Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

Author

Castañeda, Santos, Ytterberg, Steven R, Warrington, Kenneth J, Sreih, Antoine G, Spiera, Robert, Seo, Philip, Pagnoux, Christian, Moreland, Larry, Monach, Paul A, McKinnon-Maksimowicz, Kathleen, McAlear, Carol A, Langford, Carol A, Koening, Curry L, Khalidi, Nader A, Hoffman, Gary S, Forbess, Lindsay J, Cuthbertson, David, Chung, Sharon A, Carette, Simon, Karaaslan, Yasar, Ates, Askin, Ozbalkan, Zeynep, Cobankara, Veli, Kaşifoğlu, Timuçin, Alibaz-Oner, Fatma, Aydin, Sibel Z, Yentür, Sibel P, Inanc, Murat, Kamali, Sevil, Akkoc, Nurullah, Onen, FATOŞ, Akar, Servet, Pamuk, Ömer N, Kiraz, Sedat, Karadag, Omer, Duzgun, Nurşen, Bıcakcıgil, Muge, Ozturk, Mehmet A, Keser, Gokhan, Aksu, Kenan, Te Ozer, Hüseyin, Erken, Eren, Tunc, Ercan, Fresko, Izzet, Seyahi, Emire, Dalkilic, Ediz, Kısacık, Bünyamin, Yazici, Ayten, Cefle, Ayse, Mesut Onat, Ahmet, Cimmino, Marco A, Govoni, Marcello, Beretta, Lorenzo, Ramirez, Giuseppe A, Emmi, Giacomo, Addimanda, Olga, Pazzola, Giulia, Muratore, Francesco, Bonatti, Francesco, Santilli, Daniele, Gianfreda, Davide, Lunardi, Claudio, Soriano, Alessandra, Martínez-Taboada, Víctor Manuel, Prieto-González, Sergio, Blanco, Ricardo, Fanlo Mateo, Patricia, Sanchez Pernaute, Olga, Callejas, José Luis, Ríos Fernández, Raquel, Ortego-Centeno, Norberto, Guijarro Rojas, Mercedes, García-Villanueva, María Jesús, Ramentol-Sintas, Marc, Corbera-Bellalta, Marc, Pérez-Conesa, Mercedes, Sáez-Comet, Luis, Alegre-Sancho, Juan J, Sánchez-Martín, Julio, Miranda-Filloy, José A, Tío, Laura, Monfort, Jordi, Narváez, Javier, Martínez-Zapico, Aleida, Caminal-Montero, Luis, Díaz-López, J Bernardino, Morado, Inmaculada C, Martínez, Lina, López-Longo, Francisco J, de Miguel, Eugenio, Vicente, Esther F, Román, José A, Grau, Elena, Raya, Enrique, Gómez-Vaquero, Carmen, Sopeña, Bernardo, Marí-Alfonso, Begoña, Escalante, Begoña, Rodríguez-Rodríguez, Luis, Fernández-Gutiérrez, Benjamín, Ordóñez-Cañizares, M Carmen, Fernández-Nebro, Antonio, Vuelta, Ana Belén Madroñero, Hidalgo-Conde, Ana, Unzurrunzaga, Ainhoa, Martínez-Berriochoa, Agustín, Sawalha, Amr H, Martín, Javier, González-Gay, Miguel A, Salvarani, Carlo, Boiardi, Luigi, Merkel, Peter A, Direskeneli, Haner, Carmona, F David, Coit, Patrick, Saruhan-Direskeneli, Güher, Hernández-Rodríguez, José, Cid, María C, Solans, Roser, and Vaglio, Augusto

Subjects
03 medical and health sciences, 0302 clinical medicine, Multidisciplinary, Geography, Component (UML), 030221 ophthalmology & optometry, Library science, Large vessel, skin and connective tissue diseases, Article, 030217 neurology & neurosurgery
Abstract

Giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1/HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P = 7.54E-07; ORGCA = 1.19, ORTAK = 1.50). This marker was confirmed as novel GCA risk factor using four additional cohorts (PGCA = 5.52E-04, ORGCA = 1.16). Taken together, our results provide evidence of strong genetic differences between GCA and TAK in the HLA. Outside this region, common susceptibility factors were suggested, especially within the IL12B locus.

Published
2017

33. Changes in patterns of uveitis at a tertiary referral center in Northern Italy: analysis of 990 consecutive cases

Author

Salvarani Carlo, Soriano Alessandra, Aldigeri Raffaella, Fontana Luigi, Chersich Matthew, Parmeggiani Maria, Coassin Marco, Zerbini Alessandro, Belloni Lucia, Viscogliosi Fabiana, Marchi Sylvia, Mastrofilippo Valentina, Soldani Annamaria, Savoldi Luisa, Cimino Luca, and De Fanti Alessandro

Subjects
Adult, Male, medicine.medical_specialty, Pediatrics, Eye Infections, Tertiary Care Centers, Uveitis, 03 medical and health sciences, 0302 clinical medicine, Panuveitis, Epidemiology, Humans, Medicine, Ocular disease, Aged, 030203 arthritis & rheumatology, business.industry, Incidence, Middle Aged, Infection, Interdisciplinary approach, Italy, Systemic disease, medicine.disease, Uveitis, Anterior, Surgery, Northern italy, Ophthalmology, 030221 ophthalmology & optometry, Referral center, Female, Erratum, business, Uveitis, Intermediate
Abstract

The role of uveitis, an uncommon ocular disease, is often neglected in research and treatment of autoimmune conditions. The study described the spectrum of uveitis at a referral center in North Italy, and compared that to a previously published series of patients.We reviewed all patients with uveitis diagnosed from 2013 to 2015 at the Immunology Eye Unit, Arcispedale S. M. Nuova-IRCCS, Reggio Emilia, Italy. We examined patient characteristics, disease spectrum, and etiologies.In total, 990 cases of uveitis were identified, who were mostly female (59%) with a median age at presentation of 44 years (interquartile range = 29-57). Anterior uveitis was most frequent (53.5%), followed by panuveitis (22.8%), posterior (16.2%), and intermediate uveitis (5.5%). Anterior herpetic uveitis (15.6%), Fuchs uveitis (9.7%), and HLA-B27 positive anterior uveitis (7.7%) were the most common specific diagnoses. Compared with the previous series, we observed an increased incidence of uveitis, and a different pattern of diagnoses. Rates of herpetic, HLA-B27 positive uveitis, and presumed ocular tuberculosis were higher, but Fuchs uveitis was less frequent.The pattern of uveitis appears to be changing, very likely due to population-level increases in infectious diseases, to the availability of new diagnostic tests and to the interdisciplinary approach used in patient diagnosis.

Published
2017

34. Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor in Patients With Behçet Disease

Author

Bonacini, Martina, primary, Soriano, Alessandra, additional, Zerbini, Alessandro, additional, Calò, Eleonora, additional, Cimino, Luca, additional, Muratore, Francesco, additional, Fontana, Luigi, additional, Braglia, Luca, additional, Parmeggiani, Maria, additional, Salvarani, Carlo, additional, and Croci, Stefania, additional

Published
2018
Full Text
View/download PDF

35. Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care

Author

Saibeni, Simone, Scucchi, Ludovica, Dragoni, Gabriele, Bezzio, Cristina, Miranda, Agnese, Ribaldone, Davide Giuseppe, Bertani, Angela, Bossa, Fabrizio, Allocca, Mariangela, Buda, Andrea, Mocci, Gianmarco, Soriano, Alessandra, Mazzuoli, Silvia, Bertani, Lorenzo, Baccini, Flavia, Loddo, Erika, Privitera, Antonino Carlo, Sartini, Alessandro, Viscido, Angelo, Grossi, Laurino, Casini, Valentina, Gerardi, Viviana, Ascolani, Marta, Ruscio, Mirko, Casella, Giovanni, Savarino, Edoardo, Stradella, Davide, Pumpo, Rossella, Cortelezzi, Claudio Camillo, Daperno, Marco, Ciardo, Valeria, Nardone, Olga Maria, Caprioli, Flavio, Vitale, Giovanna, Cappello, Maria, Comberlato, Michele, Alvisi, Patrizia, Festa, Stefano, Campigotto, Michele, Bodini, Giorgia, Balestrieri, Paola, Viola, Anna, Pugliese, Daniela, Armuzzi, Alessandro, Fantini, Massimo C, and Fiorino, Gionata

Abstract

Restructuring activities have been necessary during the lockdown phase of the coronavirus disease 2019 (COVID-19) pandemic. Few data are available on the post-lockdown phase in terms of health-care procedures in inflammatory bowel disease (IBD) care, and no data are available specifically from IBD units. We aimed to investigate how IBD management was restructured during the lockdown phase, the impact of the restructuring on standards of care and how Italian IBD units have managed post-lockdown activities. A web-based online survey was conducted in two phases (April and June 2020) among the Italian Group for IBD affiliated units within the entire country. We investigated preventive measures, the possibility of continuing scheduled visits/procedures/therapies because of COVID-19 and how units resumed activities in the post-lockdown phase. Forty-two referral centres participated from all over Italy. During the COVID-19 lockdown, 36% of first visits and 7% of follow-up visits were regularly done, while >70% of follow-up scheduled visits and 5% of first visits were done virtually. About 25% of scheduled endoscopies and bowel ultrasound scans were done. More than 80% of biological therapies were done as scheduled. Compared to the pre-lockdown situation, 95% of centres modified management of outpatient activity, 93% of endoscopies, 59% of gastrointestinal ultrasounds and 33% of biological therapies. Resumption of activities after the lockdown phase may take three to six months to normalize. Virtual clinics, implementation of IBD pathways and facilities seem to be the main factors to improve care in the future. Italian IBD unit restructuring allowed quality standards of care during the COVID-19 pandemic to be maintained. A return to normal appears to be feasible and achievable relatively quickly. Some approaches, such as virtual clinics and identified IBD pathways, represent a valid starting point to improve IBD care in the post-COVID-19 era.

Published
2020
Full Text
View/download PDF

36. Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene

Author

Ruiz-Ortiz, Estíbaliz, primary, Iglesias, Estíbaliz, additional, Soriano, Alessandra, additional, Buján-Rivas, Segundo, additional, Español-Rego, Marta, additional, Castellanos-Moreira, Raul, additional, Tomé, Adrià, additional, Yagüe, Jordi, additional, Antón, Jordi, additional, and Hernández-Rodríguez, José, additional

Published
2017
Full Text
View/download PDF

37. A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility

Author

David Carmona, F., Mackie, Sarah L., Martin, Jose-Ezequiel, Taylor, John C., Vaglio, Augusto, Eyre, Stephen, Bossini-Castillo, Lara, Castaneda, Santos, Cid, Maria C., Hernandez-Rodriguez, Jose, Prieto-Gonzalez, Sergio, Solans, Roser, Ramentol-Sintas, Marc, Francisca Gonzalez-Escribano, M., Ortiz-Fernandez, Lourdes, Morado, Inmaculada C., Narvaez, Javier, Miranda-Filloy, Jose A., Beretta, Lorenzo, Lunardi, Claudio, Cimmino, Marco A., Gianfreda, Davide, Santilli, Daniele, Ramirez, Giuseppe A., Soriano, Alessandra, Muratore, Francesco, Pazzola, Giulia, Addimanda, Olga, Wijmenga, Cisca, Witte, Torsten, Schirmer, Jan H., Moosig, Frank, Schoenau, Verena, Franke, Andre, Palm, Oyvind, Molberg, Oyvind, Diamantopoulos, Andreas P., Carette, Simon, Cuthbertson, David, Forbess, Lindsy J., Hoffman, Gary S., Khalidi, Nader A., Koening, Curry L., Langford, Carol A., McAlear, Carol A., Moreland, Larry, Monach, Paul A., Pagnoux, Christian, Koeleman, Bobby P. C., de Bakker, Paul I. W., and Spanish GCA Grp

Subjects
PRIMARY BILIARY-CIRRHOSIS, FOXP3 EXPRESSION, TYROSINE-PHOSPHATASE PTPN22, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, NF-KAPPA-B, Journal Article, ATOPIC-DERMATITIS, POLYMYALGIA-RHEUMATICA, GENOME-WIDE ASSOCIATION, EXTENDED HUMAN MHC, RISK LOCI, RHEUMATOID-ARTHRITIS
Abstract

We conducted a large-scale genetic analysis on giant cell arteritis (GCA), a polygenic immune-mediated vasculitis. A case-control cohort, comprising 1,651 case subjects with GCA and 15,306 unrelated control subjects from six different countries of European ancestry, was genotyped by the Immunochip array. We also imputed HLA data with a previously validated imputation method to perform a more comprehensive analysis of this genomic region. The strongest association signals were observed in the HLA region, with rs477515 representing the highest peak (p = 4.05 x 10(-40), OR = 1.73). A multivariate model including class II amino acids of HLA-DR beta 1 and HLA-DQ alpha 1 and one class I amino acid of HLA-B explained most of the HLA association with GCA, consistent with previously reported associations of classical HLA alleles like HLA-DRB1*04. An omnibus test on polymorphic amino acid positions highlighted DR beta 1 13 (p = 4.08 x 10(-43)) and HLA-DQ alpha 1 47 (p = 4.02 x 10(-46)), 56, and 76 (both p = 1.84 x 10(-45)) as relevant positions for disease susceptibility. Outside the HLA region, the most significant loci included PTPN22 (rs2476601, p = 1.73 x 10(-6), OR = 1.38), LRRC32 (rs10160518, p = 4.39 x 10(-6), OR = 1.20), and REL (rs115674477, p = 1.10 x 10(-5), OR = 1.63). Our study provides evidence of a strong contribution of HLA class I and II molecules to susceptibility to GCA. In the non-HLA region, we confirmed a key role for the functional PTPN22 rs2476601 variant and proposed other putative risk loci for GCA involved in Th1, Th17, and Treg cell function.

Published
2015

38. Sjögren's syndrome presenting with isolated sensory axonal polyneuropathy

Author

Di Lazzaro, Vincenzo, Rigon, Amelia, Soriano, Alessandra, Capone, Fioravante, Corbetto, Marzia, Florio, Lucia, Afeltra, Antonella, Onetti Muda, Andrea, Luigetti, Marco, Luigetti, Marco (ORCID:0000-0001-7539-505X), Di Lazzaro, Vincenzo, Rigon, Amelia, Soriano, Alessandra, Capone, Fioravante, Corbetto, Marzia, Florio, Lucia, Afeltra, Antonella, Onetti Muda, Andrea, Luigetti, Marco, and Luigetti, Marco (ORCID:0000-0001-7539-505X)

Abstract

No abstract

Published
2016

39. A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study

Author

Vitale, Antonio, primary, Insalaco, Antonella, additional, Sfriso, Paolo, additional, Lopalco, Giuseppe, additional, Emmi, Giacomo, additional, Cattalini, Marco, additional, Manna, Raffaele, additional, Cimaz, Rolando, additional, Priori, Roberta, additional, Talarico, Rosaria, additional, Gentileschi, Stefano, additional, de Marchi, Ginevra, additional, Frassi, Micol, additional, Gallizzi, Romina, additional, Soriano, Alessandra, additional, Alessio, Maria, additional, Cammelli, Daniele, additional, Maggio, Maria C., additional, Marcolongo, Renzo, additional, La Torre, Francesco, additional, Fabiani, Claudia, additional, Colafrancesco, Serena, additional, Ricci, Francesca, additional, Galozzi, Paola, additional, Viapiana, Ombretta, additional, Verrecchia, Elena, additional, Pardeo, Manuela, additional, Cerrito, Lucia, additional, Cavallaro, Elena, additional, Olivieri, Alma N., additional, Paolazzi, Giuseppe, additional, Vitiello, Gianfranco, additional, Maier, Armin, additional, Silvestri, Elena, additional, Stagnaro, Chiara, additional, Valesini, Guido, additional, Mosca, Marta, additional, de Vita, Salvatore, additional, Tincani, Angela, additional, Lapadula, Giovanni, additional, Frediani, Bruno, additional, De Benedetti, Fabrizio, additional, Iannone, Florenzo, additional, Punzi, Leonardo, additional, Salvarani, Carlo, additional, Galeazzi, Mauro, additional, Rigante, Donato, additional, and Cantarini, Luca, additional

Published
2016
Full Text
View/download PDF

40. A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility

Author

Genetica Groep Koeleman, Child Health, CMM Groep Kaaij, Infection & Immunity, JC onderzoeksprogramma Methodologie, Cancer, David Carmona, F., Mackie, Sarah L., Martin, Jose-Ezequiel, Taylor, John C., Vaglio, Augusto, Eyre, Stephen, Bossini-Castillo, Lara, Castaneda, Santos, Cid, Maria C., Hernandez-Rodriguez, Jose, Prieto-Gonzalez, Sergio, Solans, Roser, Ramentol-Sintas, Marc, Francisca Gonzalez-Escribano, M., Ortiz-Fernandez, Lourdes, Morado, Inmaculada C., Narvaez, Javier, Miranda-Filloy, Jose A., Beretta, Lorenzo, Lunardi, Claudio, Cimmino, Marco A., Gianfreda, Davide, Santilli, Daniele, Ramirez, Giuseppe A., Soriano, Alessandra, Muratore, Francesco, Pazzola, Giulia, Addimanda, Olga, Wijmenga, Cisca, Witte, Torsten, Schirmer, Jan H., Moosig, Frank, Schoenau, Verena, Franke, Andre, Palm, Oyvind, Molberg, Oyvind, Diamantopoulos, Andreas P., Carette, Simon, Cuthbertson, David, Forbess, Lindsy J., Hoffman, Gary S., Khalidi, Nader A., Koening, Curry L., Langford, Carol A., McAlear, Carol A., Moreland, Larry, Monach, Paul A., Pagnoux, Christian, Koeleman, Bobby P. C., de Bakker, Paul I. W., Spanish GCA Grp, Genetica Groep Koeleman, Child Health, CMM Groep Kaaij, Infection & Immunity, JC onderzoeksprogramma Methodologie, Cancer, David Carmona, F., Mackie, Sarah L., Martin, Jose-Ezequiel, Taylor, John C., Vaglio, Augusto, Eyre, Stephen, Bossini-Castillo, Lara, Castaneda, Santos, Cid, Maria C., Hernandez-Rodriguez, Jose, Prieto-Gonzalez, Sergio, Solans, Roser, Ramentol-Sintas, Marc, Francisca Gonzalez-Escribano, M., Ortiz-Fernandez, Lourdes, Morado, Inmaculada C., Narvaez, Javier, Miranda-Filloy, Jose A., Beretta, Lorenzo, Lunardi, Claudio, Cimmino, Marco A., Gianfreda, Davide, Santilli, Daniele, Ramirez, Giuseppe A., Soriano, Alessandra, Muratore, Francesco, Pazzola, Giulia, Addimanda, Olga, Wijmenga, Cisca, Witte, Torsten, Schirmer, Jan H., Moosig, Frank, Schoenau, Verena, Franke, Andre, Palm, Oyvind, Molberg, Oyvind, Diamantopoulos, Andreas P., Carette, Simon, Cuthbertson, David, Forbess, Lindsy J., Hoffman, Gary S., Khalidi, Nader A., Koening, Curry L., Langford, Carol A., McAlear, Carol A., Moreland, Larry, Monach, Paul A., Pagnoux, Christian, Koeleman, Bobby P. C., de Bakker, Paul I. W., and Spanish GCA Grp

Published
2015

41. Vasculitides

Author

Shoenfeld, Yehuda, Manna, Raffaele, Soriano, Alessandra, Passaro, Giovanna, Manna, Raffaele (ORCID:0000-0003-1560-3907), Shoenfeld, Yehuda, Manna, Raffaele, Soriano, Alessandra, Passaro, Giovanna, and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Abstract

Review of literature about vaccines and Vasculitides

Published
2015

42. A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility

Author

Carmona, F. David, primary, Mackie, Sarah L., additional, Martín, Jose-Ezequiel, additional, Taylor, John C., additional, Vaglio, Augusto, additional, Eyre, Stephen, additional, Bossini-Castillo, Lara, additional, Castañeda, Santos, additional, Cid, Maria C., additional, Hernández-Rodríguez, José, additional, Prieto-González, Sergio, additional, Solans, Roser, additional, Ramentol-Sintas, Marc, additional, González-Escribano, M. Francisca, additional, Ortiz-Fernández, Lourdes, additional, Morado, Inmaculada C., additional, Narváez, Javier, additional, Miranda-Filloy, José A., additional, Beretta, Lorenzo, additional, Lunardi, Claudio, additional, Cimmino, Marco A., additional, Gianfreda, Davide, additional, Santilli, Daniele, additional, Ramirez, Giuseppe A., additional, Soriano, Alessandra, additional, Muratore, Francesco, additional, Pazzola, Giulia, additional, Addimanda, Olga, additional, Wijmenga, Cisca, additional, Witte, Torsten, additional, Schirmer, Jan H., additional, Moosig, Frank, additional, Schönau, Verena, additional, Franke, Andre, additional, Palm, Øyvind, additional, Molberg, Øyvind, additional, Diamantopoulos, Andreas P., additional, Carette, Simon, additional, Cuthbertson, David, additional, Forbess, Lindsy J., additional, Hoffman, Gary S., additional, Khalidi, Nader A., additional, Koening, Curry L., additional, Langford, Carol A., additional, McAlear, Carol A., additional, Moreland, Larry, additional, Monach, Paul A., additional, Pagnoux, Christian, additional, Seo, Philip, additional, Spiera, Robert, additional, Sreih, Antoine G., additional, Warrington, Kenneth J., additional, Ytterberg, Steven R., additional, Gregersen, Peter K., additional, Pease, Colin T., additional, Gough, Andrew, additional, Green, Michael, additional, Hordon, Lesley, additional, Jarrett, Stephen, additional, Watts, Richard, additional, Levy, Sarah, additional, Patel, Yusuf, additional, Kamath, Sanjeet, additional, Dasgupta, Bhaskar, additional, Worthington, Jane, additional, Koeleman, Bobby P.C., additional, de Bakker, Paul I.W., additional, Barrett, Jennifer H., additional, Salvarani, Carlo, additional, Merkel, Peter A., additional, González-Gay, Miguel A., additional, Morgan, Ann W., additional, Martín, Javier, additional, Martínez-Berriochoa, Agustín, additional, Unzurrunzaga, Ainhoa, additional, Hidalgo-Conde, Ana, additional, Madroñero-Vuelta, Ana B., additional, Fernández-Nebro, Antonio, additional, Ordóñez-Cañizares, M. Carmen, additional, Escalante, Begoña, additional, Marí-Alfonso, Begoña, additional, Sopeña, Bernardo, additional, Magro, César, additional, Raya, Enrique, additional, Grau, Elena, additional, Román, José A., additional, de Miguel, Eugenio, additional, López-Longo, F. Javier, additional, Martínez, Lina, additional, Gómez-Vaquero, Carmen, additional, Fernández-Gutiérrez, Benjamín, additional, Rodríguez-Rodríguez, Luis, additional, Díaz-López, J. Bernardino, additional, Caminal-Montero, Luis, additional, Martínez-Zapico, Aleida, additional, Monfort, Jordi, additional, Tío, Laura, additional, Sánchez-Martín, Julio, additional, Alegre-Sancho, Juan J., additional, Sáez-Comet, Luis, additional, Pérez-Conesa, Mercedes, additional, Corbera-Bellalta, Marc, additional, García-Villanueva, M. Jesús, additional, Fernández-Contreras, M. Encarnación, additional, Sanchez-Pernaute, Olga, additional, Blanco, Ricardo, additional, Ortego-Centeno, Norberto, additional, Ríos-Fernández, Raquel, additional, Callejas, José L., additional, Fanlo-Mateo, Patricia, additional, and Martínez-Taboada, Víctor M., additional

Published
2015
Full Text
View/download PDF

43. A retrospective analysis of 3156 admissions with fever of unknown origin in a large Italian hospital.

Author

Nicolotti, N, Cattel, Caterina, Gualano, Mr, Soriano, Alessandra, Manna, Raffaele, Boccia, Stefania, Manna, Raffaele (ORCID:0000-0003-1560-3907), Boccia, Stefania (ORCID:0000-0002-1864-749X), Nicolotti, N, Cattel, Caterina, Gualano, Mr, Soriano, Alessandra, Manna, Raffaele, Boccia, Stefania, Manna, Raffaele (ORCID:0000-0003-1560-3907), and Boccia, Stefania (ORCID:0000-0002-1864-749X)

Abstract

Background: fever of unknown origin (FUO) is defined as a fever with no etiologic diagnosis after standardized investigations performed during 3 days in hospital or after at least 3 ambulatory visits. Our study aims to describe the epidemiology of classic FUO through the retrospective analysis of 902 861 admissions to a large University Hospital in Italy, to investigate its temporal trend, and to evaluate differences between young and old patients. Methods: we retrieved data records of all the admissions between the 1st January 1988 and 31st December 2007. Proportional admission rate (PAR) of FUO was calculated. Time trends of FUO admissions were analysed by joinpoint regression, with time changes expressed as Expected Annual Percent Change (EA PC). The ICD 9-CM code was used to identify the diagnosis on discharge of FUO cases. Results: in the study period 3 156 patients were admitted with a diagnosis of FUO (PAR=3.50 per 1 000). The time-trend analysis showed two joinpoints, the first in 1995 (EAPC of 307.80, 95% CI: 89.66-776.84, p=0.002), and the second in 1998 (EAPC=-8.57, 95% CI: -10.37-6.73; p<0.001). Around 22% of admissions remained without a definitive diagnosis of FUO, with this percentage being lower in patients ≥65 years compared with subjects aged 21-64. ConclusionS: FUO is a leading cause of admission to hospitals, as well as of morbidity and mortality, thus representing a challenge for diagnostic medicine and hospital care. It is necessary to develop a diagnostic methodology for FUO, so as to reduce costs of preventable hospitalizations.

Published
2013

44. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: comparing different experiences

Author

Soriano, Alessandra, Manna, Raffaele, Manna, Raffaele (ORCID:0000-0003-1560-3907), Soriano, Alessandra, Manna, Raffaele, and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Abstract

We read with interest the letter by Wada et al. titled “Giant cell arteritis with polymyalgia rheumatica associated with influenza vaccination”.1 The authors reported the case of a previously healthy 70-year-old woman vaccinated against influenza virus a day before the onset of severe headache, pain in the bilateral shoulders and upper arms, and jaw claudication. The patient’s symptoms and laboratory results fulfilled both the 1990 American College of Rheumatology (ACR) and Bird’s criteria for giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), respectively. Influenza vaccination is a widely accepted recommendation in high-risk individuals and it can be associated with minor and transient side-effects, whereas systemic complications such as rheumatic disorders or vasculitis are rare.2 Recently, we reported the analysis of our case series of 10 previously healthy subjects who developed GCA and/or PMR following influenza vaccination and for comparison we conducted a systematic published work survey of reports on GCA and PMR occurring after influenza vaccination.3 In our case series two out of 10 patients developed GCA/PMR within 3 months of influenza vaccine, six patients developed isolated GCA and two patients developed isolated PMR. The GCA diagnosis was established according the ACR criteria and PMR according to the Healey criteria. Our published work survey yielded four isolated cases of GCA following influenza vaccination: over the cases already cited by Wada et al., we found that in 2008 Pou et al.4 reported another case of isolated GCA 1 week after influenza vaccination had been administrated to a 74-year-old patient. Regarding the coexistence of GCA and PMR following vaccination, in 2001 Saadoun et al.5 reported the case of a 64-year-old woman with a previous diagnosis of PMR in clinical remission after steroid therapy, who developed headache, joint claudication and cough 3 days after influenza vaccination, in absence of polymyalgic symptoms or visual

Published
2012

45. Quantifying the efficacy of influenza vaccines

Author

Soriano, Alessandra, Manna, Raffaele, Manna, Raffaele (ORCID:0000-0003-1560-3907), Soriano, Alessandra, Manna, Raffaele, and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Abstract

In their meta-analysis of the efficacy and effectiveness of influenza vaccines licensed in the USA, Michael Osterholm and colleagues1 stated that “evidence for protection in adults aged 65 years or older is lacking”, although chronic disorders such as cardiac and pulmonary diseases could require influenza vaccination. The cost-effectiveness of influenza vaccination policy requires consideration of adverse effects such as autoimmune disorders, which are rarely reported. Possible reasons for disregarding these events include the subacute presentation in some cases and the variable latency period (from days to years), which makes ascertainment of the causality link difficult.2 The 1976 national influenza immunisation programme against swine flu subtype A/NJ/76 in the USA was stopped because of the emergence of Guillain-Barré syndrome in some vaccine recipients. The USA, the UK, and Germany have initiated active surveillance studies to detect potential rare adverse events, and “the overall risk–benefit assessments must be interpreted very carefully, since the composition of annual influenza vaccines varies each season“3 and the risk of side-effects might depend on the subtype, or adjuvants, or both. For the past few years, all post-vaccination events have been included in the spectrum of autoimmune or inflammatory syndrome induced by adjuvants, because of previous exposure to immune adjuvants, including those used in vaccines to boost an immune response.4 In our Periodic Fevers Research Centre, which admits patients with fever of unknown origin, over 6 years we identified ten cases of giant cell arteritis or polymyalgia rheumatica, occurring within 3 months of influenza vaccination. A Medline search from 1978 to 2011 showed 11 isolated cases of the same disorders happening after influenza vaccination.5 Such disorders are common in people older than 65 years, who are a major target of influenza vaccination policy. In the Comment accompanying Osterholm and colleagues' me

Published
2012

46. Familial Mediterranean fever: New phenotypes

Author

Soriano, Alessandra, Manna, Raffaele, Manna, Raffaele (ORCID:0000-0003-1560-3907), Soriano, Alessandra, Manna, Raffaele, and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Abstract

Familial Mediterranean fever (FMF) is an inherited autosomal recessive disorder, ethnically restricted and commonly found among individuals of Mediterranean descent, caused by MEditerranean FeVer gene (MEFV) mutations on chromosome 16. It is the most frequent periodic febrile syndrome among the autoinflammatory syndromes. Clinically, FMF can be distinguished into three phenotypes: type 1, which is commonly associated with recurrent short episodes of inflammation and serositis, including fever, peritonitis, synovitis, pleuritis, but also pericarditis, orchitis or meningitis episodes; type 2, characterized by the evidence of reactive amyloid-associated (AA) amyloidosis, the most severe complication of FMF, as the first clinical manifestation of the disease in an otherwise asymptomatic individual; type 3, referred to the 'silent' homozygous or compound heterozygote state, in which two MEFV mutations are detected without signs or symptoms of FMF nor of AA amyloidosis. In the recent years it has been observed that also heterozygous mutation carriers can suffer from a mild or incomplete form of FMF, named 'FMF-like' disease. The influence of other modifiers genes and/or environmental factors can contribute to the variable penetrance and to the phenotypic variability of FMF. The insight into complex clinical and genetic cases will provide adjunctive details for the comprehension of the mechanisms of this kaleidoscopic disease.

Published
2012

47. Polymyalgia rheumatica in 2011

Author

Soriano, Alessandra, Landolfi, Raffaele, Manna, Raffaele, Landolfi, Raffaele (ORCID:0000-0002-7913-8576), Manna, Raffaele (ORCID:0000-0003-1560-3907), Soriano, Alessandra, Landolfi, Raffaele, Manna, Raffaele, Landolfi, Raffaele (ORCID:0000-0002-7913-8576), and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Abstract

Polymyalgia Rheumatica (PMR) is an inflammatory rheumatic disease that commonly affects individuals over 50 years of age, characterised by pain and morning stiffness of the shoulder and pelvic girdle. PMR can present as 'isolated' form or may be associated with giant cell arteritis. The progress of imaging techniques has helped in understanding different clinical patterns: subclinical vasculitis can occur in at least one-third of PMR patients, causing ischaemic complications. It is considered a polygenic disease and environmental factors may play a role in its pathogenesis, such as viral or bacterial triggers, both in the 'wide' form or assembled with adjuvants in vaccines. The response to steroid therapy is generally dramatic and side effects may occur, as well as the development of glucocorticoid resistance. The optimisation of therapy may require steroid-sparing agents as well as modified-release prednisone as 'nighttime' replacement therapy.

Published
2012

48. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature

Author

Soriano, Alessandra, Verrecchia, Elisa Carla Bianca, Marinaro, Alessia, Giovinale, Maria, Fonnesu, Claudia, Landolfi, Raffaele, Manna, Raffaele, Landolfi, Raffaele (ORCID:0000-0002-7913-8576), Manna, Raffaele (ORCID:0000-0003-1560-3907), Soriano, Alessandra, Verrecchia, Elisa Carla Bianca, Marinaro, Alessia, Giovinale, Maria, Fonnesu, Claudia, Landolfi, Raffaele, Manna, Raffaele, Landolfi, Raffaele (ORCID:0000-0002-7913-8576), and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Abstract

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are inflammatory rheumatic diseases common in people over the age of 50 years. Herein, we report 10 cases of previously healthy subjects who developed GCA/PMR within 3 months of influenza vaccination (Inf-V). A Medline search uncovered additional 11 isolated cases of GCA/PMR occurring after Inf-V. We discuss the role of individual susceptibility, the potential function of immune adjuvants as triggers of autoimmunity post-vaccination, and the correlation of our observation with the 'ASIA' syndrome, i.e. autoimmune/inflammatory syndrome induced by adjuvants and including post-vaccination phenomena.

Published
2012

49. Febbre ed ipertermia

Author

Gasbarrini, Giovanni, Gricelli, Claudio, S.M.G., GASBARRINI, ANTONIO, Manna, Raffaele, Soriano, Alessandra, Verrecchia, Elena, Manna, Raffaele (ORCID:0000-0003-1560-3907), Gasbarrini, Giovanni, Gricelli, Claudio, S.M.G., GASBARRINI, ANTONIO, Manna, Raffaele, Soriano, Alessandra, Verrecchia, Elena, and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Published
2010

50. Cyclosporine A: good response for patients affected by autoimmune disorders and HCV infection?

Author

Manna, Raffaele, Verrecchia, Elena, Fonnesu, Claudia, Giovinale, Maria, De Socio, Giuliana, Curigliano, Valentina, Cerquaglia, Claudia, Soriano, Alessandra, Gasbarrini, Giovanni Battista, Manna, Raffaele (ORCID:0000-0003-1560-3907), Manna, Raffaele, Verrecchia, Elena, Fonnesu, Claudia, Giovinale, Maria, De Socio, Giuliana, Curigliano, Valentina, Cerquaglia, Claudia, Soriano, Alessandra, Gasbarrini, Giovanni Battista, and Manna, Raffaele (ORCID:0000-0003-1560-3907)

Abstract

INTRODUCTION: In autoimmune disorders (ADs), if Hepatitis C Virus (HCV) is present, immunosuppressive treatment could increase virus replication. Cyclosporine A (CsA), in standard therapeutic doses, has been proven able to inhibit HCV cyclophilin in vitro. Therefore CsA could improve the therapy of HCV patients with ADs. AIM: In these patients, we started an open pilot study to evaluate the safety of 3 mg/kg CsA and the ability to reduce steroid therapy. PATIENTS AND METHODS: Five females and 1 male were recruited; mean age 66 +/- 8 years, mean disease duration 13 +/- 5 years. Three patients are affected by Psoriasic Arthritis, 1 by Rheumatoid Arthritis, 1 by Sjogren Syndrome, and 1 by Myasthenia Gravis. None of them had chronic active hepatitis. HCV genotypes were type 2 (in 3 cases) and type 1 (in 3 cases). Patients were treated with 3 mg/kg of CsA for a period of time ranging from 6 to 12 months. The starting mean dose of prednisone was 12.5 mg/day. Liver function tests were checked monthly and serum HCV-RNA load was checked by RT-PCR before and 2 months into the therapy. RESULTS: The prednisone dose was reduced from 12.5 mg/day to 7.5 mg/day. The aminotransferases levels were unchanged after 6 months. In patients with low HCV-RNA levels before treatment, no modifications of viral load were observed, whereas patients with increased levels at onset showed mild reduction 2 months into the treatment. CONCLUSIONS: Immunosuppressive treatment of ADs patients with HCV infection can be safely provided with the integration of CsA.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results